Cambridge

Horizontal Tabs

Overview

Summary

The Cambridge ECMC aims to develop molecular prognostic and diagnostic tests to aid treatment decisions. The Centre focuses on genetic predisposition to cancer and the identification of high risk groups. This is being achieved by building on local strengths in genomics, pharmacogenetics, molecular pathology, molecular imaging, clinical informatics and computational biology.

The overall aim of the Cambridge ECMC is to deliver personliased cancer medicine as the means to better achieve cancer control as the means to better achieve cancer control. This personalistion of cancer medicine used the detailed characterisations of both the neoplasm and of the patient afflicated by it to improve screening, diagnosis, trageted treatment, and treatment monitoring.

Cancer control will be ultimately achieved through prevention, through early diagnosis, through better use of currently available treatments, and through the development of new better targeted therapeutics. The Cambridge ECMC provide support related to each of these areas.

As of 2017-2022 quinquennium, the Cambridge ECMC is also a member of the Paediatric Network.

In particular, the Cambridge ECMC will provide infrastructure support for 6 broad research areas:

Early-phase clinical trials and experimental therapeutics
Tumour monitoring (advanced cancer imaging)
Tumour monitoring (liquid biopsy, cf DNA)
Predictive biomarkers
Translational research in late-phase trials
Screening and intervention in high-risk groups

Organisations affiliated with the Cambridge ECMC:

Contact the Centre Manager:

Si-Houy Lao-Sirieix
sihouy@addenbrookes.nhs.uk

Address

Cambridge Cancer Trials Centre
Ward S4
Addenbrooke's Hospital
Cambridge, CB2 0RE

Tel: 01223 348396

Team Members

Professor Duncan Jodrell

Centre Lead

duncan.jodrell@cruk.cam.ac.uk

+44 (0) 122 376 9750

PA: phyllis.smith@addenbrookes.nhs.uk

Professor Jodrell's work endeavours to integrate and optimise the pre-clinical development and science-led clinical application of novel therapies and novel therapeutic combinations, including first into man (Phase I) and associated studies. His research goal is to identify successful, new therapeutic approaches for the treatment of patients with cancer with much of effort now focusing on pancreatic cancer.

Operational Team

Lesley Bennett

R&D Contact

lesley.bennett1@addenbrookes.nhs.uk

Linda Jones

Senior Research Sister

linda.jones@addenbrookes.nhs.uk

+44 (0) 122 323 6422

Dr Ferdia Gallagher

Lead Radiologist

fag1000@cam.ac.uk

+ 44 (0) 122 374 6438

Pia Fagelman

Haematology Trials and Data Manager

pia.fagelman@Addenbrookes.nhs.uk

+44 (0) 122 325 6193

Rebecca Brais

Consultant Histopathologis

rebecca.brais@addenbrookes.nhs.uk

Dr Michael Williams

PKB Core Facility Head

michael.williams@cruk.cam.ac.uk

Anita Chhabra

Lead Pharmacist

anita.chhabra@addenbrookes.nhs.uk

Cathy Thorbison

CCTC Sample Collection Lead

cathy.thorbison@addenbrookes.nhs.uk

Beverley Haynes

Biobank Contact

beverley.haynes@addenbrookes.nhs.uk

+44 (0) 122 325 6689

Case Studies

FDG-PET - quantitative measurements in ovarian cancer

For patients with recurrent ovarian cancer, there is an urgent need to identify more effective therapies. An imaging tool that can robustly identify early response would be of value both in the clinical setting and as a biomarker for drug development.

The FDG-PET study in ovarian cancer with Dr Andrea Rockall and colleagues from the Cambridge ECMC was able to demonstrate good repeatability of quantitive FDG-PET/ CT across two sites. An accurate baseline means that this technology could be used to monitor metabolic and/or volumetric response to treatment in platinum-sensitive relapsed ovarian cancer.

The detection of changes in tumor glucose metabolism, tumor diameter, or tumor volume within a few weeks of commencing treatment has the potential to inform stratification of patient management. Validation of imaging biomarkers is critical for effective and reliable use in clinical trials. Test–retest data for measurements of 2[18F]fluoro-2-deoxy-D-glucose (FDG) uptake, tumor diameter, and tumor volume are essential to determine repeatability coefficients, thereby allowing the confident use of these techniques. This is the first time repeatability of these baseline measures has been tested in ovarian cancer.

The team in Cambridge are now seeking to include novel PET tracers in early phase trials including 15O-water and 18F-MISO in the VDF study of bevacizumab for patients with kidney cancer.

Rockall et.al., Clin Cancer Res May 15, 2014 20; 2751

Treatment Modalities

Cytotoxic therapeutics

Immunotherapy

Molecular Targeted Therapies

Radiotherapy

Surgery

Facilities/Translational Research

Phase 1 Capability

Phase 1 population: Both solid tumours and haematology, adult
Phase 1 Mechanisms: Taxanes, TKI inhibitors, Kudos compound
First-in-Man studies
Centre specific translational research interest: Molecular imaging, clinical genomics
Multi-centre Phase 1 studies

Technology/equipment available within the centre

3T MRI facility
Genomics and bioinformatics
Molecular pathology
Equipment for isolation of circulating tumour cells

Other Facilities

Wellcome Trust CRF
Cambridge Breast Cancer Research Unit
Cambridge Cancer Clinical Trials Centre

Sample collection

Tissue Banking Activity: Addenbrooke's Tissue Bank
Centre contact responsible for sample collection: Professor Peter Collins

ECMC funding provides infrastructure support for early phase and translational research. From the ECMC Cambridge portfolio, the following trials have been carried out.

Trial activity between 2012-2015:

Trial by disease type between 2012-2015:

You are here

Horizontal Tabs

Operational Team